

## Understanding Pharmacoepidemiology and Real-World Evidence Studies

14-16 April 2026 | 09:00-13:00 CEST



### Overview

Evidence generated from observational studies using real-world data (RWD), outside of clinical trials, known as real-world evidence (RWE), is increasingly being used to inform decision-making regarding the use of medicines.

The use of RWE has gone beyond its usual domains of pharmacovigilance, pharmaco-economic and outcomes research. RW studies are now conducted during the whole lifecycle of medicines, to enhance drug discovery and development, as well as their contribution to studying post-authorisation safety and effectiveness. The potential for the use of RWE throughout the entire lifecycle of medicines will continue to grow.

Everyone working in biomedical sciences needs to understand the principles, methods and applications of observational RW studies.

### Learning Objectives

- Identify the basic principles of real-world studies
- Observational study designs and methods
- Their strengths and weaknesses
- Applications and examples of real-world studies

### Key Topics

- The basic principles of studying Real World Data (RWD)
- Strengths of RWD (representing patients in the real world, including large numbers of patients)
- Weaknesses (chance, bias, confounding, missing data, misclassification)
- The differences (and complementarity) between clinical trials and observational studies
- Describe observational study designs (cross sectional, cohort, case-control studies)
- Describe the role of registries in biomedical research
- Examples of observational studies during the whole lifecycle of medicines
- The expansion of RWE and RWD

### Who Will Attend

This virtual live training course is designed for professionals with prior experience in biomedical research and clinical trials. Participants mostly to benefit from this course include, but are not limited to, pharmacovigilance executives, study managers, and pharmaceutical physicians seeking to deepen their knowledge and enhance their practical skills.

### Faculty

#### Saad Shakir

Pharmacovigilance Physician and Pharmacoepidemiologist  
United Kingdom

#### Ben Bray

Health data science, Epidemiology, Real world evidence, GenAI  
United Kingdom

#### Xabier Garcia de Albeniz Martinez

Director, Epidemiology, RTI Health Solutions  
Spain

#### Jesper Hallas

Professor, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark  
Denmark

#### Deborah Layton

Director of Drug Safety, IQVIA  
United Kingdom

#### Andrea Margulis

Senior Director, Epidemiology, RTI Health Solutions  
Spain

**DAY 1****09:00 WELCOME AND INTRODUCTION****09:10 SESSION 1****THE VALUE OF REAL-WORLD DATA****Saad Shakir**

This session will provide a high-level overview of real-world evidence (RWE) which is the foundation for the following lectures. The critical components of typical RWE studies and their strengths and limitations will be introduced. An overview of randomised controlled trials (RCTs) will be provided, including their different objectives. The differences in internal and external validity between RCTs and RWS will be explained. It will describe the complementary positioning of RWD to RCTs for evidence generation. It will provide a brief overview of how RWD is used in understanding the safety and effectiveness of medicines and vaccines, post-authorisation safety and effectiveness studies (PASS and PAES). The increase in use and importance of RWE across the product lifecycle will be described.

**09:40 SESSION 2****BASIC PRINCIPLES OF OBSERVATIONAL REAL-WORLD STUDIES****Saad Shakir and Deborah Layton**

This session will build on Session 1 and dive deeper into how the concept of risk can be quantified (basic measures of disease frequency, association and impact) together with assessing uncertainty. The common challenges of RWE studies that affect interpretation will be introduced such as bias, confounding, missing information, and misclassification.

**10:30 BREAK****10:50 SESSION 3****BASIC PRINCIPLES OF OBSERVATIONAL REAL-WORLD STUDY METHODS****Deborah Layton**

Building further on the first two sessions, the main types of descriptive and comparative study designs will be introduced in the context of safety studies, alongside an overview of general methods on how to handle common challenges. Methods described will be cross sectional, case-control and cohort studies.

**11:30 SESSION 4****SELF-CONTROLLED STUDIES****Jesper Hallas**

This session will describe the self-controlled designs which are used for investigating associations between treatments and outcomes while automatically controlling for time-invariant confounding, even if unmeasured or unknown.

**12:00 BREAK****12:10 INTERACTIVE SESSION****13:00 END OF DAY 1****DAY 2****09:00 INTRODUCTION TO DAY 2****09:05 SESSION 5****SOURCES OF REAL-WORLD DATA****Deborah Layton**

This session will describe how RWD are obtained, what are commonly used types of RWD sources and will introduce the concept of “fitness for use” and approaches to ensure data used are reliable, relevant and robust. It will describe the role of registries in generating RWE.

**09:40 SESSION 6****FRAMING AND DESIGNING A COMPARATIVE RWE STUDY****Xabier Garcia de Albeniz**

This session will introduce causal inference methods, including the Target Trial Emulation approach which provides a framework for causal inference in the non-randomised setting and can be used to design comparative RWE studies.

**10:30 BREAK****10:50 SESSION 7****TOOLKIT FOR RWE GENERATION****Xabier Garcia de Albeniz**

This session will present the following resources for RWE generation: “SPIFD2” framework (to evaluate RWD fitness for use), “PRINCIPLED” guideline (for the design of studies using RWD), “HARPER” protocol template for RWD studies, “ROBINS-I”, a quality-assessment tool to evaluate the risk of bias and the “TARGET” reporting guidelines for target trial emulations.

**11:30 INTERACTIVE SESSION****13:00 END OF DAY 2**

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.

**DAY 3****09:00 INTRODUCTION TO DAY 3****09:05 SESSION 8****APPLICATIONS OF RWS: RISK MANAGEMENT AND EFFECTIVENESS OF RISK MINIMISATION****Saad Shakir and Xabier Garcia de Albeniz**

This session will present regulatory applications to leverage RWD in risk management addressing requests from the European Medicines Agency in different therapeutic areas.

**09:50 SESSION 9****APPLICATIONS OF RWS: SAFETY IN PREGNANCY****Andrea Margulis**

Pregnant women are usually barely represented in clinical trials. Therefore, RWE has a prominent role in the safety evaluation of drugs taken during pregnancy. This session will review specific challenges of RWE generation in this population and introduce solutions.

**10:30 BREAK****10:50 SESSION 10****THE ROLE OF RWE IN OUTCOMES RESEARCH AND HEALTH TECHNOLOGY ASSESSMENT****Ben Bray**

How RWE is used in regulatory, payer and clinical decision-making contexts, particularly in outcomes research and comparative effectiveness research studies will be described. The concept of sequential decision making will be explored in relation to how RWE can inform decisions that are made across the lifecycle of a medical product - from development and regulatory approval to payer coverage and clinical implementation. Finally, the increasing use of RWE in supporting expedited authorisations will be described with real world examples presented where RWE has contributed to faster access.

**11:30 SESSION 11****RISK BENEFIT BALANCE****Saad Shakir**

In this session the concept of risk-benefit (RB) balance will be defined including its role in the whole lifecycle of medicinal products. The principles of causality and causal inference in evaluating adverse events and therapeutic outcomes will be explained through application of the Bradford Hill criteria to assess causal relationships between medicinal products and observed effects. An overview will be provided of the methods for both conventional risk-benefit evaluation and formal semi-quantitative methods for RB evaluation. The evolution of RB evaluation across the lifecycle of products will be described.

**12:10 BREAK****12:20 QUESTIONS AND ANSWERS****12:50 CLOSING SESSION****13:00 END OF THE TRAINING COURSE**

*Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.*



## Group Discounts

**Register 3 individuals from the same company for the same course and receive complimentary registration for a 4th!\***

To take advantage of this offer, please print the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together via email to [basel@diaglobal.org](mailto:basel@diaglobal.org).

*\*Terms and Conditions apply. Please contact DIA EMEA office for more information.*



## Customized Professional Development for Your Team

Get a customized training for your department (or even across different departments!) and benefit from increased:

- Knowledge of a topic of your choice
- Flexibility & Convenience
- Cost Effectiveness

Or explore [eLearning](#) to allow self-paced learning.

For more information please contact [basel@diaglobal.org](mailto:basel@diaglobal.org)



## About DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation has its Global Center in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China



## Technical Requirements

To test your system compatibility, please click on the link: <https://diaglobal.zoom.us/test>

For further information on system requirements, please visit the website:  
<https://www.diaglobal.org/General/System-Requirements>



## Continuing Education

The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 7 credits.



# REGISTRATION FORM

Understanding PE and RWE Studies | Virtual Live Training Course # 26592  
14-16 April 2026 | 09:00-13:00 CEST

## REGISTRATION FEES

Registration fee includes full admission to virtual course, electronic access to training course materials.  
**Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material.** Please check:

FEES	MEMBER EARLY-BIRD valid until 17 Mar 2026	MEMBER valid from 18 Mar 2026	NON- MEMBER
INDUSTRY/ REPRESENTATIVE	€ 1'215.00 <input type="checkbox"/>	€ 1'350.00 <input type="checkbox"/>	€ 1'610.00 <input type="checkbox"/>
ACADEMIA/CHARITABLE/GOVERNMENT/NON-PROFIT (FULL-TIME)	NA	€ 675.00 <input type="checkbox"/>	€ 935.00 <input type="checkbox"/>
<u>A special discount is available for organisations which are listed in the EMA SME register.</u> Number of discounted seats is limited.			

All registration fees are subject to VAT if applicable.

Please enter your company's VAT number: \_\_\_\_\_

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

**Payment is due 30 days after registration and must be paid in full by commencement of the course.**

### DIA MEMBERSHIP

All nonmember fees include a one year DIA membership, at no additional cost. Explore membership benefits at [DIAglobal.org/Membership](https://www.diaglobal.org/Membership).

DIA membership will renew automatically at the end of the complimentary membership term, at the then current membership rates. You may cancel automatic membership renewal at any time by accessing your account online at [DIAglobal.org](https://www.diaglobal.org). If you would like to decline complimentary membership, please indicate your preference below.

☐ I would like to decline a one year complimentary DIA membership.

The DIA Contact Centre Team will be pleased to assist you with your registration from Monday to Friday between 09:00 and 17:00 CE(S)T. **Tel.** :+41 61 225 51 51

**Email:** [Basel@DIAglobal.org](mailto:Basel@DIAglobal.org) **Mail:** DIA, Küchengasse 16, 4051 Basel, Switzerland

**Web:** [www.DIAglobal.org](https://www.DIAglobal.org)

## ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

☐ Prof ☐ Dr ☐ Ms ☐ Mr

Last Name

First Name

Job Title

Company

Address

Postal Code

City

Country

Telephone Number

Attendee email required for course material access

## TERMS AND CONDITIONS

### Cancellation Policy

All cancellations must be made in writing and be received at the DIA office four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00

If you do not cancel four weeks prior to the event start date and do not attend, you will be responsible for the full registration fee.

**DIA reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.**

### Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA office of any such substitutions as soon as possible.

### Event Stream and Recording

If you attend a DIA event, we make video and audio recordings of events (both face-to-face and online) that may include your participation in the event, including your image, questions and comments. To view our full photography and video recording policy, click <https://www.diaglobal.org/general/photography-policy>.

### Privacy Policy

DIA respects the privacy of all of its members and customers. To view our privacy policy, click <https://www.diaglobal.org/about-us/privacy-policy>.

## PAYMENT METHOD

DIA accepts only Credit Card as a payment method.

Payments by VISA, Mastercard or AMEX are accepted. Other types of credit card are not accepted.

You will receive a payment link in the coming days to complete the payment.

Please complete payment within 7 days of receipt of the payment link.

Payments will be net of all charges and bank charges will be borne by the payer.

**If you have not received your confirmation within five working days, please contact [basel@diaglobal.org](mailto:basel@diaglobal.org).**

By signing below, I confirm that I read and agree with DIA's Terms and Conditions of booking.

These are available from the office or online by clicking:

<http://www.diaglobal.org/EUterms>

Date

Signature